

SARS-CoV-2 Omicron variant replication in human bronchial epithelial cells

Nature

603, 715-720

DOI: [10.1038/s41586-022-04479-6](https://doi.org/10.1038/s41586-022-04479-6)

Citation Report

#	ARTICLE	IF	CITATIONS
7	Charge Matters: Mutations in Omicron Variant Favor Binding to Cells. <i>ChemBioChem</i> , 2022, 23, e202100681.	1.3	62
10	Clinical profile of patients infected with suspected SARS-CoV-2 Omicron variant of concern, Tamil Nadu, India, December 2021-January 2022. <i>Indian Journal of Medical Research</i> , 2022, 155, 165.	0.4	13
12	Omicron's lasting mysteries: four questions scientists are racing to answer. <i>Nature</i> , 2022, 603, 22-24.	13.7	11
18	Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. <i>Nature Medicine</i> , 2022, 28, 1063-1071.	15.2	398
19	Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike's ACE2 Interaction. <i>ACS Central Science</i> , 2022, 8, 527-545.	5.3	62
20	Assessment of BIV1-Covlran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern. <i>Clinical Microbiology and Infection</i> , 2022, 28, 882.e1-882.e7.	2.8	7
21	Coronavirus disease 2019 (COVID-19)-related smell and taste impairment with widespread diffusion of severe acute respiratory syndrome-coronavirus (SARS-CoV-2) Omicron variant. <i>International Forum of Allergy and Rhinology</i> , 2022, 12, 1273-1281.	1.5	82
22	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401.	12.5	135
24	Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant. <i>BMC Medicine</i> , 2022, 20, 102.	2.3	67
28	Challenges of the Omicron (B.1.1.529) Variant and Its Lineages: A Global Perspective. <i>ChemBioChem</i> , 2022, 23, e202200059.	1.3	35
29	Mucus secretion blocked at its source in the lungs. <i>Nature</i> , 2022, 603, 798-799.	13.7	1
30	The genomic and clinical features of the COVID-19 Omicron variant: a narrative review. <i>F1000Research</i> , 0, 11, 353.	0.8	1
32	SARS-CoV-2 Omicron variant: Immune escape and vaccine development. <i>MedComm</i> , 2022, 3, e126.	3.1	74
33	Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. <i>Cell</i> , 2022, 185, 1539-1548.e5.	13.5	126
35	COVID-19 Cases and Disease Severity in Pregnancy and Neonatal Positivity Associated With Delta (B.1.617.2) and Omicron (B.1.1.529) Variant Predominance. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1500.	3.8	59
36	Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. <i>Lancet, The</i> , 2022, 399, 1618-1624.	6.3	547
37	Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. <i>Nature Medicine</i> , 2022, 28, 1491-1500.	15.2	239
38	Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. <i>Lancet, The</i> , 2022, 399, 1303-1312.	6.3	889

#	ARTICLE	IF	CITATIONS
39	Omicron: Understanding the latest variant of SARS-CoV-2 and strategies for tackling the infection. ChemBioChem, 2022, , .	1.3	4
40	Deep Learning Applied to Chest Radiograph Classification—A COVID-19 Pneumonia Experience. Applied Sciences (Switzerland), 2022, 12, 3712.	1.3	6
42	Modeling insights into SARS-CoV-2 respiratory tract infections prior to immune protection. Biophysical Journal, 2022, 121, 1619-1631.	0.2	17
43	The non-pharmaceutical interventions may affect the advantage in transmission of mutated variants during epidemics: A conceptual model for COVID-19. Journal of Theoretical Biology, 2022, 542, 111105.	0.8	5
45	Croup Associated With SARS-CoV-2: Pediatric Laryngotracheitis During the Omicron Surge. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 371-374.	0.6	16
46	Is There Less Alteration of Smell Sensation in Patients With Omicron SARS-CoV-2 Variant Infection?. Frontiers in Medicine, 2022, 9, 852998.	1.2	25
51	Visualizing omicron: COVID-19 deaths vs. cases over time. PLoS ONE, 2022, 17, e0265233.	1.1	12
53	New Variants in SARS-CoV-2: What are we Learning from the Omicron Variant?. Archivos De Bronconeumologia, 2022, 58, 3-5.	0.4	2
54	COVID-19: Omicron — the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. Microbial Biotechnology, 2022, 15, 1927-1939.	2.0	41
55	Analytical Sensitivity of Six SARS-CoV-2 Rapid Antigen Tests for Omicron versus Delta Variant. Viruses, 2022, 14, 654.	1.5	44
56	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs, 2022, 36, 231-323.	2.2	24
58	Reduced Replication Efficacy of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in —Mini-gut—Organoids. Gastroenterology, 2022, 163, 514-516.	0.6	15
59	SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduction and Targeted Therapy, 2022, 7, 141.	7.1	315
60	Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events. Signal Transduction and Targeted Therapy, 2022, 7, 138.	7.1	140
61	Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages. MSphere, 2022, 7, e0091321.	1.3	8
63	SARS-CoV-2 Virion Infectivity and Cytokine Production in Primary Human Airway Epithelial Cells. Viruses, 2022, 14, 951.	1.5	6
64	The rapid replacement of the SARS-CoV-2 Delta variant by Omicron (B.1.1.529) in England. Science Translational Medicine, 2022, 14, eabo5395.	5.8	40
65	SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Cell Host and Microbe, 2022, 30, 1103-1111.e6.	5.1	38

#	ARTICLE	IF	CITATIONS
66	Clinical Characteristics of COVID-19 Patients Infected by the Omicron Variant of SARS-CoV-2. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	39
67	Omicron: increased transmissibility and decreased pathogenicity. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 151.	7.1	99
68	When and which patients should receive remdesivir?. <i>Lancet, The</i> , 2022, 399, 1918-1920.	6.3	2
69	Croup during the Coronavirus Disease 2019 Omicron Variant Surge. <i>Journal of Pediatrics</i> , 2022, 247, 147-149.	0.9	26
70	Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model. <i>JCI Insight</i> , 2022, 7, .	2.3	24
71	BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality. <i>Nature Microbiology</i> , 2022, 7, 909-917.	5.9	41
72	Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection. <i>Virology</i> , 2022, 572, 64-71.	1.1	12
73	At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	11
74	<sc>SARSâ€CoV</sc>â€2 airway reactivity in children: more of the same?. <i>Anaesthesia</i> , 2022, 77, 956-958.	1.8	1
81	Role of COVID-19 Vaccines in SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	37
82	Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021â€January 2022: A retrospective, population-based, matched cohort study. <i>EClinicalMedicine</i> , 2022, 48, 101455.	3.2	49
83	A qualitative RT-PCR assay for the specific identification of the SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern. <i>Journal of Clinical Virology</i> , 2022, 152, 105191.	1.6	15
84	Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. <i>The Lancet Global Health</i> , 2022, 10, e961-e969.	2.9	120
85	Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021â€February 2022. <i>Emerging Infectious Diseases</i> , 2022, 28, 1355-1365.	2.0	18
86	Replication of SARS-CoV-2 Omicron BA.2 Variant in <i>Ex Vivo</i> Cultures of the Human Upper and Lower Respiratory Tract. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
87	Omicron Infection Induces Low-Level, Narrow-Range SARS-CoV-2 Neutralizing Activity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
88	Analysis of the Transmission of SARS-CoV-2 Delta VOC in Yantai, China, August 2021. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	0
91	Protective neutralizing epitopes in SARSâ€CoVâ€2. <i>Immunological Reviews</i> , 2022, 310, 76-92.	2.8	23

#	ARTICLE	IF	CITATIONS
93	Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. <i>Nature Microbiology</i> , 2022, 7, 896-908.	5.9	32
96	Evaluation of Four Point of Care (POC) Antigen Assays for the Detection of the SARS-CoV-2 Variant Omicron. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	15
97	Differential Pathogenesis of SARS-CoV-2 Variants of Concern in Human ACE2-Expressing Mice. <i>Viruses</i> , 2022, 14, 1139.	1.5	21
98	Multicompartmental Mathematical Model of SARS-CoV-2 Distribution in Human Organs and Their Treatment. <i>Mathematics</i> , 2022, 10, 1925.	1.1	5
99	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	5.1	50
100	Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19. <i>ACS Infectious Diseases</i> , 2022, 8, 1191-1203.	1.8	4
101	Rear Windowâ€”What Can the Gut Tell Us About Long-COVID?. <i>Gastroenterology</i> , 2022, 163, 376-378.	0.6	6
102	The wave of the SARS-CoV-2 Omicron variant resulted in a rapid spike and decline as highlighted by municipal wastewater surveillance. <i>Environmental Technology and Innovation</i> , 2022, 28, 102667.	3.0	22
103	Treating patients infected with the SARS-CoV-2 Omicron variant with a traditional Chinese medicine, Shufeng Jiedu capsule. <i>BioScience Trends</i> , 2022, 16, 238-241.	1.1	12
104	How should designated COVID-19 hospitals in megacities implement a precise management strategy in response to Omicron?. <i>BioScience Trends</i> , 2022, 16, 242-244.	1.1	3
105	The Effects of Vaccination on the Diseaseâ€™Severityâ€™And Factors for Viral Clearanceâ€™And Hospitalization in Omicron-Infectedâ€™Patientsâ€™Retrospective Observational Cohort Study from Recent Regional Outbreaks in China. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
106	The Spike Protein of SARS-CoV-2 Is Adapting Because of Selective Pressures. <i>Vaccines</i> , 2022, 10, 864.	2.1	17
107	Immuno-epidemiology and the predictability of viral evolution. <i>Science</i> , 2022, 376, 1161-1162.	6.0	13
108	Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. <i>Clinical Microbiology Reviews</i> , 2022, 35, .	5.7	35
109	ACE2, a drug target for COVID-19 treatment?. <i>Irish Journal of Medical Science</i> , 0, , .	0.8	0
110	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
111	The past, current and future epidemiological dynamic of SARS-CoV-2. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	24
112	A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants. <i>Viruses</i> , 2022, 14, 1369.	1.5	26

#	ARTICLE	IF	CITATIONS
113	SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters. <i>Nature Communications</i> , 2022, 13, .	5.8	73
114	Competition of SARS-CoV-2 Variants in Cell Culture and Tissue: Wins the Fastest Viral Autowave. <i>Vaccines</i> , 2022, 10, 995.	2.1	3
115	Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. <i>International Journal of Translational Medicine</i> , 2022, 2, 275-308.	0.1	1
117	The Awesome Power of Human Genetics of Infectious Disease. <i>Annual Review of Genetics</i> , 2022, 56, 41-62.	3.2	5
118	Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
119	Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. <i>Science</i> , 2022, 377, 428-433.	6.0	113
120	SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2267-2273.	2.0	10
121	Reduction in Chest CT Severity and Improved Hospital Outcomes in SARS-CoV-2 Omicron Compared with Delta Variant Infection. <i>Radiology</i> , 2023, 306, 261-269.	3.6	53
122	Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. <i>Science</i> , 2022, 377, .	6.0	241
123	Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections. <i>Emerging Microbes and Infections</i> , 2022, 11, 1742-1750.	3.0	43
124	Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. <i>Nature Medicine</i> , 2022, 28, 1933-1943.	15.2	243
125	BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative Design. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
126	SARS-CoV-2 Omicron BA.5: Evolving Tropism and Evasion of Potent Humoral Responses and Resistance to Clinical Immunotherapeutics Relative to Viral Variants of Concern. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
127	The nervous system during COVID-19: Caught in the crossfire. <i>Immunological Reviews</i> , 2022, 311, 90-111.	2.8	9
128	Chest CT Findings in Hospitalized Patients with SARS-CoV-2: Delta versus Omicron Variants. <i>Radiology</i> , 2023, 306, 252-260.	3.6	33
129	Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	7
131	Case Report: The Experience of Managing a Moderate ARDS Caused by SARS-CoV-2 Omicron BA.2 Variant in Chongqing, China: Can We Do Better?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
132	Evaluation of Two Broadly Used Commercial Methods for Detection of Respiratory Viruses with a Recently Added New Target for Detection of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1530.	1.5	5

#	ARTICLE	IF	CITATIONS
134	Omicron Binding Mode: Contact Analysis and Dynamics of the Omicron Receptor-Binding Domain in Complex with ACE2. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 3844-3853.	2.5	11
135	COVID-19: Challenges of Viral Variants. <i>Annual Review of Medicine</i> , 2023, 74, 31-53.	5.0	43
136	Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters. <i>Journal of Infectious Diseases</i> , 2023, 227, 1143-1152.	1.9	16
137	Recent clinical findings on the role of kinase inhibitors in COVID-19 management. <i>Life Sciences</i> , 2022, 306, 120809.	2.0	10
138	Incidence and severity of SARS-CoV-2 infections in liver and kidney transplant recipients in the post-vaccination era: Real-life data from Denmark. <i>American Journal of Transplantation</i> , 2022, 22, 2637-2650.	2.6	22
139	Influence of Nasopharyngeal Viral Load on the Spread of the Omicron BA.2 Variant. <i>Clinical Infectious Diseases</i> , 2023, 76, e514-e517.	2.9	7
140	Guardians of the oral and nasopharyngeal galaxy: <scp>IgA</scp> and protection against <scp>SARSâ€CoV</scp>â€2 infection*. <i>Immunological Reviews</i> , 2022, 309, 75-85.	2.8	32
145	Novel Lateral Flow-Based Assay for Simple and Visual Detection of SARS-CoV-2 Mutations. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	1
146	New SARS-CoV-2 Omicron variant â€” clinical picture, treatment, prevention (literature review). <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2022, 21, 3228.	0.4	9
147	Intrinsic generation time of the SARS-CoV-2 Omicron variant: An observational study of household transmission. <i>Lancet Regional Health - Europe</i> , The, 2022, 19, 100446.	3.0	34
148	Progressive membrane-binding mechanism of SARS-CoV-2 variant spike proteins. <i>IScience</i> , 2022, 25, 104722.	1.9	8
149	A severe presentation of breakthrough infection caused by the Omicron variant with radiological findings of COVID-19 pneumonia in an elderly woman. <i>Radiology Case Reports</i> , 2022, 17, 3326-3330.	0.2	2
150	Vitamin D levels and clinical outcomes of SARS-CoV-2 Omicron subvariant BA.2 in children: A longitudinal cohort study. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	9
151	Cutaneous manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348 691 UK users of the UK ZOE COVID Study app. <i>British Journal of Dermatology</i> , 2022, 187, 900-908.	1.4	13
152	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197.	1.8	46
153	Alveolar macrophages: Achillesâ€™ heel of SARS-CoV-2 infection. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	15
155	A Case Report of Breakthrough Infections With 2 SARS-CoV-2 Variants in a Lung Transplant Patient. <i>Transplantation Proceedings</i> , 2022, 54, 2698-2701.	0.3	0
156	Risk of Reinfection, Vaccine Protection, and Severity of Infection with the BA.5 Omicron Subvariant: A Danish Nation-Wide Population-Based Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	17

#	ARTICLE	IF	CITATIONS
157	Methylene blue, Mycophenolic acid, Posaconazole, and Niclosamide inhibit SARS-CoV-2 Omicron variant BA.1 infection of human airway epithelial organoids. <i>Current Research in Microbial Sciences</i> , 2022, 3, 100158.	1.4	4
159	The genomic and clinical features of the COVID-19 Omicron variant: a narrative review. <i>F1000Research</i> , 0, 11, 353.	0.8	0
160	Evolution of ACE2-independent SARS-CoV-2 infection and mouse adaption after passage in cells expressing human and mouse ACE2. <i>Virus Evolution</i> , 2022, 8, .	2.2	14
161	SARS-CoV-2 Omicron Induces Enhanced Mucosal Interferon Response Compared to other Variants of Concern, Associated with Restricted Replication in Human Lung Tissues. <i>Viruses</i> , 2022, 14, 1583.	1.5	13
162	Initial observations of Jinhua Qinggan Granules, a Chinese medicine, in the mitigation of hospitalization and mortality in high-risk elderly with COVID-19 infection: A retrospective study in an old age home in Hong Kong. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
165	COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron). <i>ELife</i> , 0, 11, .	2.8	36
166	Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
167	Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology. <i>Vaccine</i> , 2022, 40, 5892-5903.	1.7	6
168	Computational Analysis of Short Linear Motifs in the Spike Protein of SARS-CoV-2 Variants Provides Possible Clues into the Immune Hijack and Evasion Mechanisms of Omicron Variant. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8822.	1.8	1
169	Uninvited Guest: Arrival and Dissemination of Omicron Lineage SARS-CoV-2 in St. Petersburg, Russia. <i>Microorganisms</i> , 2022, 10, 1676.	1.6	5
171	Infection with the Omicron variant of SARS-CoV-2 is associated with less severe disease in hospitalized patients with COVID-19. <i>Journal of Infection</i> , 2022, 85, e152-e154.	1.7	10
173	Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants. <i>Pharmaceuticals</i> , 2022, 15, 1002.	1.7	3
175	Clinical characteristics of pediatric patients with COVID-19 between Omicron era vs. pre-Omicron era. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1501-1505.	0.8	14
177	Post COVID-19 condition of the Omicron variant of SARS-CoV-2. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1546-1551.	0.8	36
178	Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2693-2700.	1.3	41
179	Evolution of throat symptoms during the COVID-19 pandemic in the US. <i>Diagnosis</i> , 2022, .	1.2	4
180	Comparative symptomatology of infection with SARS-CoV-2 variants Omicron (B.1.1.529) and Delta (B.1.617.2) from routine contact tracing data in England. <i>Epidemiology and Infection</i> , 2022, 150, .	1.0	11
181	A fast, ultrasensitive SERS immunoassay to detect SARS-CoV-2 in saliva. <i>Analytica Chimica Acta</i> , 2022, 1229, 340290.	2.6	18

#	ARTICLE	IF	CITATIONS
182	Comparison of COVID-19 pneumonia during the SARS-CoV-2 Omicron wave and the previous non-Omicron wave in a single facility. <i>Respiratory Investigation</i> , 2022, 60, 772-778.	0.9	17
183	Introduction, Spread and Impact of the SARS-CoV-2 Omicron Variants BA.1 and BA.2 in Cyprus. <i>Microorganisms</i> , 2022, 10, 1688.	1.6	2
184	A comprehensive modelling approach to estimate the transmissibility of coronavirus and its variants from infected subjects in indoor environments. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
185	Covid-19: is omicron less lethal than delta?. <i>BMJ, The</i> , 0, , o1806.	3.0	20
186	Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine. <i>Cell Reports Medicine</i> , 2022, 3, 100716.	3.3	16
187	Interferon β -2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: An open prospective cohort study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
188	Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19. <i>Journal of Integrative Medicine</i> , 2022, 20, 488-496.	1.4	4
189	Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tract. <i>EBioMedicine</i> , 2022, 83, 104232.	2.7	48
190	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522.	2.5	56
191	SARS-CoV-2 and COVID-19: A Narrative Review. , 0, 79, .		9
193	The importance of booster vaccination in the context of Omicron wave. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
194	Laboratory markers of severity across three COVID-19 outbreaks in Australia: has Omicron and vaccinations changed disease presentation?. <i>Internal and Emergency Medicine</i> , 2023, 18, 43-52.	1.0	8
195	Photochemical Identification of Auxiliary Severe Acute Respiratory Syndrome Coronavirus 2 Host Entry Factors Using $\frac{1}{4}$ Map. <i>Journal of the American Chemical Society</i> , 2022, 144, 16604-16611.	6.6	8
196	Mortality Risk Among Patients Hospitalized Primarily for COVID-19 During the Omicron and Delta Variant Pandemic Periods â€” United States, April 2020â€”June 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 1182-1189.	9.0	100
198	Molecular dynamics simulations highlight the altered binding landscape at the spike-ACE2 interface between the Delta and Omicron variants compared to the SARS-CoV-2 original strain. <i>Computers in Biology and Medicine</i> , 2022, 149, 106035.	3.9	14
199	SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. <i>EBioMedicine</i> , 2022, 84, 104270.	2.7	86
200	The mechanisms of immune response and evasion by the main SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 105044.	1.9	8
201	Clinical Progression and Outcome of Hospitalized Patients Infected with SARS-CoV-2 Omicron Variant in Shanghai, China. <i>Vaccines</i> , 2022, 10, 1409.	2.1	9

#	ARTICLE	IF	CITATIONS
205	âœLymphocyte * Neutrophilâ€count decreased in <sc>SARSâ€CoV</sc>â€2 Omicron patients in Shanghai with no significant change in <sc>CRP</sc> and <sc>SAA</sc>. Journal of Clinical Laboratory Analysis, 2022, 36, .	0.9	8
206	The Evolving Scenario of COVID-19 in Hemodialysis Patients. International Journal of Environmental Research and Public Health, 2022, 19, 10836.	1.2	3
207	Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants. Frontiers in Public Health, 0, 10, .	1.3	7
208	COVID-19 is Observed in Older Children During the Omicron Wave in New York City. Journal of Emergency Medicine, 2023, 64, 195-199.	0.3	4
209	A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. Frontiers in Immunology, 0, 13, .	2.2	7
210	SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria. PLoS ONE, 2022, 17, e0274509.	1.1	8
211	COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in Zambia, 2021â€2022. Open Forum Infectious Diseases, 2022, 9, .	0.4	7
212	Drug repurposing and sequence analysis in S-glycoprotein variants reveals critical signature patterns and destabilization of receptor-binding domain in omicron variant. Journal of Biomolecular Structure and Dynamics, 2023, 41, 7931-7948.	2.0	0
214	The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants. Journal of Virology, 2022, 96, .	1.5	6
215	Kidney health in the COVID-19 pandemic: An umbrella review of meta-analyses and systematic reviews. Frontiers in Public Health, 0, 10, .	1.3	7
216	Computed Tomographic Imaging Features of COVID-19 Pneumonia Caused by the Delta (B.1.617.2) and Omicron (B.1.1.529) Variant in a German Nested Cohort Pilot Study Group. Tomography, 2022, 8, 2435-2449.	0.8	12
217	Molecular Insights into Striking Antibody Evasion of SARS-CoV-2 Omicron Variant. Chinese Physics Letters, 2022, 39, 108701.	1.3	3
218	Microbiological and Clinical Findings of SARS-CoV-2 Infection after 2 Years of Pandemic: From Lung to Gut Microbiota. Diagnostics, 2022, 12, 2143.	1.3	4
220	Pneumococcal meningitis secondary to otitis media in two patients with COVID-19 omicron variant. International Journal of Emergency Medicine, 2022, 15, .	0.6	5
221	Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-Type and Delta SARS-CoV-2 Pneumonia. Lung, 2022, 200, 573-577.	1.4	11
223	A Study on the Nature of SARS-CoV-2 Using the Shell Disorder Models: Reproducibility, Evolution, Spread, and Attenuation. Biomolecules, 2022, 12, 1353.	1.8	2
224	Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. Cell, 2022, 185, 3992-4007.e16.	13.5	167
225	Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study. Infection, 2023, 51, 749-757.	2.3	11

#	ARTICLE	IF	CITATIONS
227	Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. <i>Lancet Respiratory Medicine</i> , 2023, 11, 176-187.	5.2	17
228	A hybrid discrete-continuum model of immune responses to SARS-CoV-2 infection in the lung alveolar region, with a focus on interferon induced innate response. <i>Journal of Theoretical Biology</i> , 2022, 555, 111293.	0.8	5
230	The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 phenotype. <i>Nature Communications</i> , 2022, 13, .	5.8	26
233	The human disease gene LYSET is essential for lysosomal enzyme transport and viral infection. <i>Science</i> , 2022, 378, .	6.0	28
234	Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. <i>EClinicalMedicine</i> , 2022, 54, 101680.	3.2	22
235	SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask. <i>Yonsei Medical Journal</i> , 2022, 63, 977.	0.9	7
236	Characteristics of post-Wuhan COVID-19 outbreaks in mainland China. , 2022, 2, 7.		1
237	Transitional Changes in Fatigue-Related Symptoms Due to Long COVID: A Single-Center Retrospective Observational Study in Japan. <i>Medicina (Lithuania)</i> , 2022, 58, 1393.	0.8	9
238	No correlation of neutralizing antibody titers against the Omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough Omicron infections among healthcare workers. <i>Journal of Infection</i> , 2022, 85, e177-e180.	1.7	6
240	Antibody protection from SARS-CoV-2 respiratory tract exposure and infection. <i>Journal of Theoretical Biology</i> , 2023, 557, 111334.	0.8	5
242	SARS-CoV-2 Omicron variant is attenuated for replication in a polarized human lung epithelial cell model. <i>Communications Biology</i> , 2022, 5, .	2.0	34
243	Etiology and Epidemiology of Croup before and throughout the COVID-19 Pandemic, 2018â€“2022, South Korea. <i>Children</i> , 2022, 9, 1542.	0.6	2
244	Exhaled Breath Aerosol Shedding of Highly Transmissible Versus Prior Severe Acute Respiratory Syndrome Coronavirus 2 Variants. <i>Clinical Infectious Diseases</i> , 2023, 76, 786-794.	2.9	22
245	Early pathogenesis profiles across SARS-CoV-2 variants in K18-hACE2 mice revealed differential triggers of lung damages. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
246	Operative Protocol for Testing the Efficacy of Nasal Filters in Preventing Airborne Transmission of SARS-CoV-2. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 13790.	1.2	3
247	Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 167-176.	4.6	71
248	Omicron SARS-CoV-2 Spike-1 Proteinâ€™s Decreased Binding Affinity to ð±7nAChr: Implications for Autonomic Dysregulation of the Parasympathetic Nervous System and the Cholinergic Anti-Inflammatory Pathwayâ€™ An In Silico Analysis. <i>BioMedInformatics</i> , 2022, 2, 553-564.	1.0	2
249	Comparison of SARS-CoV-2 Viral Loads in the Nasal Mucosa of Patients Infected With BA.1, BA.2, or BA.5 Omicron Lineages. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	2

#	ARTICLE	IF	CITATIONS
251	COVID-19 Symptoms and Duration of Rapid Antigen Test Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron BA.1 Periods. <i>JAMA Network Open</i> , 2022, 5, e2235844.	2.8	28
252	Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. <i>Nature</i> , 2022, 612, 540-545.	13.7	60
253	Using machine learning models to predict the duration of the recovery of COVID-19 patients hospitalized in Fangcang shelter hospital during the Omicron BA. 2.2 pandemic. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
254	Omicron Wave SARS-CoV-2 Diagnosis: Evaluation of Saliva, Anterior Nasal, and Nasopharyngeal Swab Samples. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	7
255	Variable detection of Omicron-BA.1 and -BA.2 by SARS-CoV-2 rapid antigen tests. <i>Medical Microbiology and Immunology</i> , 2023, 212, 13-23.	2.6	8
256	The effects of vaccination on the disease severity and factors for viral clearance and hospitalization in Omicron-infected patients: A retrospective observational cohort study from recent regional outbreaks in China. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	8
257	SARS-CoV-2 variants: Impact on biological and clinical outcome. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
259	Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies. <i>Cell Reports Medicine</i> , 2022, 3, 100850.	3.3	32
260	Human early syncytiotrophoblasts are highly susceptible to SARS-CoV-2 infection. <i>Cell Reports Medicine</i> , 2022, 3, 100849.	3.3	12
261	Evaluation of the presence of SARS-CoV-2 in vaginal and anal swabs of women with omicron variants of SARS-CoV-2 infection. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
262	Relative infectivity of the SARS-CoV-2 Omicron variant in human alveolar cells. <i>IScience</i> , 2022, 25, 105571.	1.9	2
263	Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. <i>Nature Communications</i> , 2022, 13, .	5.8	65
264	Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial. <i>Journal of Clinical Virology</i> , 2022, 157, 105328.	1.6	10
265	Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
266	SARS-CoV-2 infection in children evaluated in an ambulatory setting during Delta and Omicron time periods. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
267	Analytical performance of the rapid qualitative antigen kit for the detection of SARS-CoV-2 during widespread circulation of the Omicron variant. <i>Journal of Infection and Chemotherapy</i> , 2023, 29, 257-262.	0.8	4
268	Neurological Manifestations of hospitalized patients with mild to moderate infection with SARS-CoV-2 Omicron variant in Shanghai, China. <i>Journal of Infection and Public Health</i> , 2023, 16, 155-162.	1.9	9
269	Severe COVID-19 outcomes in pediatrics: an observational cohort analysis comparing Alpha, Delta, and Omicron variants. <i>The Lancet Regional Health Americas</i> , 2023, 18, 100405.	1.5	26

#	ARTICLE	IF	CITATIONS
270	SARS-CoV-2 Omicron Variant Genomic Sequences and Their Epidemiological Correlates Regarding the End of the Pandemic: In Silico Analysis. <i>JMIR Bioinformatics and Biotechnology</i> , 0, 4, e42700.	0.4	2
271	Reaching the Final Endgame for Constant Waves of COVID-19. <i>Viruses</i> , 2022, 14, 2637.	1.5	5
272	Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review. <i>Medicina (Lithuania)</i> , 2022, 58, 1733.	0.8	2
273	Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence. <i>Journal of Interferon and Cytokine Research</i> , 2023, 43, 246-256.	0.5	4
275	Antibody Titer Correlates with Omicron Infection in Vaccinated Healthcare Workers. <i>Viruses</i> , 2022, 14, 2605.	1.5	3
276	COVID-19 Pneumonia: Clinical Manifestations. <i>Clinics in Chest Medicine</i> , 2022, , .	0.8	0
277	Comparing the demographics and laboratory biomarkers of the COVID-19 Omicron wave and the Alpha wave in a predominantly Afro-Caribbean patient population in New York City. <i>Pneumonia (Nathan Qld)</i> , 2022, 14, .	2.5	1
278	Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529). <i>BMC Medicine</i> , 2022, 20, .	2.3	13
279	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. <i>Biochemical Society Transactions</i> , 2022, 50, 1643-1658.	1.6	6
280	Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2. <i>Epidemiology and Infection</i> , 2023, 151, .	1.0	3
281	The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts. <i>International Journal of Infectious Diseases</i> , 2022, , .	1.5	5
283	Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa. <i>Clinical Infectious Diseases</i> , 2023, 76, 1468-1475.	2.9	15
284	Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. <i>Nature Communications</i> , 2022, 13, .	5.8	17
285	Molecular Pathogenesis of Fibrosis, Thrombosis and Surfactant Dysfunction in the Lungs of Severe COVID-19 Patients. <i>Biomolecules</i> , 2022, 12, 1845.	1.8	5
286	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.5	1
287	Genome Evolution and Early Introductions of the SARS-CoV-2 Omicron Variant in Mexico. <i>Virus Evolution</i> , 2022, 8, .	2.2	3
288	Comparison of Clinical Presentation and Vaccine Effectiveness Among Omicron and Non-omicron SARS Coronavirus-2 Patients. <i>Cureus</i> , 2022, , .	0.2	3
289	SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15480.	1.8	7

#	ARTICLE	IF	CITATIONS
290	A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. <i>Cell Reports</i> , 2023, 42, 111903.	2.9	34
291	Post COVID-19 irritable bowel syndrome. <i>Gut</i> , 2023, 72, 484-492.	6.1	17
292	A randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19. <i>International Journal of Infectious Diseases</i> , 2023, 128, 148-156.	1.5	2
293	Population-Based Analysis of the Immunoglobulin G Response to Different COVID-19 Vaccines in Brazil. <i>Vaccines</i> , 2023, 11, 21.	2.1	0
294	Recent developments in the immunopathology of COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 369-388.	2.7	33
295	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong. <i>The Lancet Regional Health - Western Pacific</i> , 2023, 32, 100660.	1.3	9
296	Alpha and Omicron SARS-CoV-2 Adaptation in an Upper Respiratory Tract Model. <i>Viruses</i> , 2023, 15, 13.	1.5	1
297	Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2022, 12, .	1.6	18
298	Clinical Epidemiology of Pediatric Coronavirus Disease 2019 and its Postacute Sequelae. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 066-074.	0.8	0
299	Mucociliary transport deficiency and disease progression in Syrian hamsters with SARS-CoV-2 infection. <i>JCI Insight</i> , 2023, 8, .	2.3	6
300	A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. <i>Viruses</i> , 2023, 15, 167.	1.5	87
301	Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation. <i>Nature</i> , 2023, 615, 143-150.	13.7	52
303	Attenuation and Degeneration of SARS-CoV-2 Despite Adaptive Evolution. <i>Cureus</i> , 2023, , .	0.2	0
304	Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. <i>Viruses</i> , 2023, 15, 175.	1.5	33
305	New RT-PCR Assay for the Detection of Current and Future SARS-CoV-2 Variants. <i>Viruses</i> , 2023, 15, 206.	1.5	11
306	Rapid transmission and tight bottlenecks constrain the evolution of highly transmissible SARS-CoV-2 variants. <i>Nature Communications</i> , 2023, 14, .	5.8	17
307	An Integrated Radiologic-Pathologic Understanding of COVID-19 Pneumonia. <i>Radiology</i> , 2023, 306, .	3.6	11
308	Analysis of SARS-CoV-2 Cases, COVID-19 Outcomes and Vaccinations, during the Different SARS-CoV-2 Variants in Greece. <i>Vaccines</i> , 2023, 11, 126.	2.1	2

#	ARTICLE	IF	CITATIONS
309	Mapping of functional SARS-CoV-2 receptors in human lungs establishes differences in variant binding and SLC1A5 as a viral entry modulator of hACE2. <i>EBioMedicine</i> , 2023, 87, 104390.	2.7	3
310	Clinical characteristics and risk factors analysis of viral shedding time in mildly symptomatic and asymptomatic patients with SARS-CoV-2 Omicron variant infection in Shanghai. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
312	Human Coronavirus Cell Receptors Provide Challenging Therapeutic Targets. <i>Vaccines</i> , 2023, 11, 174.	2.1	2
313	SARS-CoV-2 variant biology: immune escape, transmission and fitness. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	160
314	Effect of nasal irrigation in adults infected with Omicron variant of COVID-19: A quasi-experimental study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
315	Genomic surveillance of SARS-CoV-2 upsurge in India due to Omicron sub-lineages BA.2.74, BA.2.75 and BA.2.76. , 2023, 11, 100148.		2
316	Potential of green tea EGCG in neutralizing SARS-CoV-2 Omicron variant with greater tropism toward the upper respiratory tract. <i>Trends in Food Science and Technology</i> , 2023, 132, 40-53.	7.8	12
318	Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. <i>Medical Microbiology and Immunology</i> , 2023, 212, 103-122.	2.6	18
319	The frequency of defective genomes in Omicron differs from that of the Alpha, Beta and Delta variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
320	Huashi baidu granule in the treatment of pediatric patients with mild coronavirus disease 2019: A single-center, open-label, parallel-group randomized controlled clinical trial. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
322	SARS-CoV-2 Vaccination and Clinical Presentation of COVID-19 in Patients Hospitalized during the Delta- and Omicron-Predominant Periods. <i>Journal of Clinical Medicine</i> , 2023, 12, 961.	1.0	1
324	The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5 Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung Microvascular Endothelial Cells. <i>Viruses</i> , 2023, 15, 332.	1.5	5
325	SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19. <i>Diagnostics</i> , 2023, 13, 559.	1.3	12
328	Comparison of culture-competent virus shedding duration of SARS-CoV-2 Omicron variant in regard to vaccination status: A prospective cohort study. <i>Vaccine</i> , 2023, 41, 2769-2772.	1.7	2
329	Clinical outcomes and phylogenetic analysis in reflection with three predominant clades of SARS-CoV-2 variants. <i>European Journal of Clinical Investigation</i> , 2023, 53, .	1.7	12
330	CFD modelling of infection control in indoor environments: A focus on room-level air recirculation systems. <i>Energy and Buildings</i> , 2023, 288, 113033.	3.1	6
331	SARS-CoV-2 Omicron variant shedding during respiratory activities. <i>International Journal of Infectious Diseases</i> , 2023, 131, 19-25.	1.5	5
332	Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19. <i>European Journal of Medicinal Chemistry</i> , 2023, 254, 115380.	2.6	4

#	ARTICLE	IF	CITATIONS
333	Modeling identifies variability in SARS-CoV-2 uptake and eclipse phase by infected cells as principal drivers of extreme variability in nasal viral load in the 48h post infection. <i>Journal of Theoretical Biology</i> , 2023, 565, 111470.	0.8	5
334	Assessing Transmission Risks of SARS-COV-2 Omicron Variant In U.S. School Facilities and Mitigation Measures. , 2022, , .		0
335	Cardiologic Manifestations in Omicron-type Versus Wild-type COVID-19: A Systematic Echocardiographic Study. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	5
336	Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. <i>Heliyon</i> , 2023, 9, e13285.	1.4	4
337	Chronological changes of viral shedding in adult inpatients with Omicron infection in Shanghai, China. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
338	Clinical Outcomes of Omicron Variant (B.1.1.529) Infection in Children and Adolescents Hospitalized With COVID-19 in Brazil With Observational Data on the Efficacy of the Vaccines in Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2023, 42, 218-225.	1.1	4
339	SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection. <i>Nature Communications</i> , 2023, 14, .	5.8	25
340	SARS-CoV-2 Omicron Subvariants Balance Host Cell Membrane, Receptor, and Antibody Docking via an Overlapping Target Site. <i>Viruses</i> , 2023, 15, 447.	1.5	1
341	A Protein Co-Conservation Network Model Characterizes Mutation Effects on SARS-CoV-2 Spike Protein. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3255.	1.8	4
342	Evaluation of possible COVID-19 reinfection in children: A multicenter clinical study. <i>Archives De Pediatrie</i> , 2023, 30, 187-191.	0.4	2
343	Evaluation of COVID-19 vaccines in primary prevention against infections and reduction in severity of illness following the outbreak of SARS-CoV-2 omicron variant in Shanghai. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
344	Inflammatory Biomarkers Differ among Hospitalized Veterans Infected with Alpha, Delta, and Omicron SARS-CoV-2 Variants. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 2987.	1.2	5
345	The risk of mortality and severe illness in patients infected with the omicron variant relative to delta variant of SARS-CoV-2: a systematic review and meta-analysis. <i>Irish Journal of Medical Science</i> , 2023, 192, 2897-2904.	0.8	2
346	SARS-CoV-2 BA.2 (Omicron) variant infection in pediatric liver transplanted recipients and cohabitants during 2022 Shanghai outbreak: a prospective cohort. <i>Virology Journal</i> , 2023, 20, .	1.4	2
347	Comparing SARS-CoV-2 variants among children and adolescents in Germany: relative risk of COVID-19-related hospitalization, ICU admission and mortality. <i>Infection</i> , 2023, 51, 1357-1367.	2.3	7
348	COVID-19 Cluster in the Hematology/Respirology Ward of a University Hospital during the Seventh Wave of the SARS-CoV-2 Pandemic in Japan: A Descriptive Study. <i>Internal Medicine</i> , 2023, , .	0.3	0
349	A novel antiviral formulation containing caprylic acid inhibits SARS-CoV-2 infection of a human bronchial epithelial cell model. <i>Journal of General Virology</i> , 2023, 104, .	1.3	2
350	Clinical Characteristics and Outcomes of Children With SARS-CoV-2 Infection During the Delta and Omicron Variant-Dominant Periods in Korea. <i>Journal of Korean Medical Science</i> , 2023, 38, .	1.1	12

#	ARTICLE	IF	CITATIONS
351	Computational analysis of the sequence-structure relation in SARS-CoV-2 spike protein using protein contact networks. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
352	Integrative network pharmacology and in silico analyses identify the anti-omicron SARS-CoV-2 potential of eugenol. <i>Heliyon</i> , 2023, 9, e13853.	1.4	4
353	Comparison of clinical characteristics and outcomes of critically ill adults with SARS-CoV-2 infection during Delta and Omicron variant predominance periods: a single-hospital retrospective cohort study. <i>BMJ Open Respiratory Research</i> , 2023, 10, e001274.	1.2	1
354	Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants. <i>Metabolites</i> , 2023, 13, 309.	1.3	13
355	Children's Symptoms with a Febrile Illness and a Positive or Negative Test of SARS-CoV-2 during the Omicron Wave. <i>Children</i> , 2023, 10, 419.	0.6	1
357	Trend and Co-occurrence Network of COVID-19 Symptoms From Large-Scale Social Media Data: Infoveillance Study. <i>Journal of Medical Internet Research</i> , 0, 25, e45419.	2.1	1
358	BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies. <i>PLoS Pathogens</i> , 2023, 19, e1011196.	2.1	6
359	Lung tropism in hospitalized patients following infection with SARS-CoV-2 variants from D614G to Omicron BA.2. <i>Communications Medicine</i> , 2023, 3, .	1.9	5
360	Variants of SARS-CoV-2: Influences on the Vaccines' Effectiveness and Possible Strategies to Overcome Their Consequences. <i>Medicina (Lithuania)</i> , 2023, 59, 507.	0.8	5
361	Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice. <i>Viruses</i> , 2023, 15, 687.	1.5	4
362	Different clinical features in Malawian outpatients presenting with COVID-19 prior to and during Omicron variant dominance: A prospective observational study. <i>PLOS Global Public Health</i> , 2023, 3, e0001575.	0.5	2
363	Comparison of Symptoms Associated With SARS-CoV-2 Variants Among Children in Canada. <i>JAMA Network Open</i> , 2023, 6, e232328.	2.8	15
365	Transmission of SARS-CoV-2 Omicron Variant under a Dynamic Clearance Strategy in Shandong, China. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	2
366	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
367	Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6,037,144 coronavirus disease 2019-positive patients. <i>Clinical Microbiology and Infection</i> , 2023, 29, 835-844.	2.8	29
369	Omicron-induced interferon signaling prevents influenza A H1N1 and H5N1 virus infection. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
370	Binding and inactivation of human coronaviruses, including SARS-CoV-2, onto purified clinoptilolite-tuff. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
371	Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. <i>Nature Communications</i> , 2023, 14, .	5.8	11

#	ARTICLE	IF	CITATIONS
372	A Phase 1, Randomized, Double-Blinded, Placebo-Controlled and Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Intranasal DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults. <i>Vaccines</i> , 2023, 11, 723.	2.1	3
373	Impact of Changes in Human Airway Epithelial Cellular Composition and Differentiation on SARS-CoV-2 Infection Biology. <i>Journal of Innate Immunity</i> , 2023, 15, 562-580.	1.8	2
374	The Isolation and In Vitro Differentiation of Primary Fetal Baboon Tracheal Epithelial Cells for the Study of SARS-CoV-2 Host-Virus Interactions. <i>Viruses</i> , 2023, 15, 862.	1.5	2
375	Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level. <i>EBioMedicine</i> , 2023, 90, 104545.	2.7	17
376	SARS-CoV-2 Variants Show Different Host Cell Proteome Profiles With Delayed Immune Response Activation in Omicron-Infected Cells. <i>Molecular and Cellular Proteomics</i> , 2023, 22, 100537.	2.5	2
378	The disease severity of COVID-19 caused by Omicron variants: A brief review. <i>Annals of Clinical Epidemiology</i> , 2023, 5, 31-36.	0.3	2
379	Within-host genetic diversity of SARS-CoV-2 lineages in unvaccinated and vaccinated individuals. <i>Nature Communications</i> , 2023, 14, .	5.8	10
380	Role of FokI rs2228570 and Tru9I rs757343 Polymorphisms in the Mortality of Patients Infected with Different Variants of SARS-CoV-2. <i>Archives of Medical Research</i> , 2023, 54, 310-318.	1.5	5
381	Clinical Characteristics of SARS-CoV-2 Omicron Cases in Pune, Maharashtra, India. <i>Cureus</i> , 2023, , .	0.2	0
382	The evolution of SARS-CoV-2. <i>Nature Reviews Microbiology</i> , 2023, 21, 361-379.	13.6	239
383	Development and external validation of prediction models for critical outcomes of unvaccinated COVID-19 patients based on demographics, medical conditions and dental status. <i>Heliyon</i> , 2023, 9, e15283.	1.4	0
384	SARS-CoV-2 infection aggravates cigarette smoke-exposed cell damage in primary human airway epithelia. <i>Virology Journal</i> , 2023, 20, .	1.4	4
385	Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	11
386	Gut distress and intervention via communications of SARS-CoV-2 with mucosal exposome. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	0
387	Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. <i>Cell Reports</i> , 2023, 42, 112443.	2.9	59
388	Associations between SARS-CoV-2 infection and incidence of new chronic condition diagnoses: a systematic review. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	3
390	Plasmablasts in previously immunologically naïve COVID-19 patients express markers indicating mucosal homing and secrete antibodies cross-reacting with SARS-CoV-2 variants and other beta-coronaviruses. <i>Clinical and Experimental Immunology</i> , 0, , .	1.1	0
391	Therapeutic strategies for COVID-19: progress and lessons learned. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 449-475.	21.5	112

#	ARTICLE	IF	CITATIONS
392	Trends in Severe Outcomes Among Adult and Pediatric Patients Hospitalized With COVID-19 in the Canadian Nosocomial Infection Surveillance Program, March 2020 to May 2022. <i>JAMA Network Open</i> , 2023, 6, e239050.	2.8	8
393	Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses. <i>PLoS Pathogens</i> , 2023, 19, e1010870.	2.1	11
394	Exhaled aerosols among PCR-confirmed SARS-CoV-2-infected children. <i>Frontiers in Pediatrics</i> , 0, 11, .	0.9	0
400	Accelerating antiviral drug discovery: lessons from COVID-19. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 585-603.	21.5	25
403	Evolutionary characteristics of SARS-CoV-2 Omicron subvariants adapted to the host. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	3
444	Epidemiology, clinical presentation, pathophysiology, and management of long COVID: an update. <i>Molecular Psychiatry</i> , 2023, 28, 4056-4069.	4.1	6
497	Understanding the Omicron Variant in the COVID-19 Pandemic. , 0, , .		0
536	SARS-CoV-2 biology and host interactions. <i>Nature Reviews Microbiology</i> , 2024, 22, 206-225.	13.6	1
540	Importance of Timely Sequencing, Tracking, and Surveillance of Emergent Variants. , 2024, , 166-193.		0